Organon & Co. (OGN) News
Filter OGN News Items
OGN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
OGN News Highlights
- For OGN, its 30 day story count is now at 2.
- Over the past 3 days, the trend for OGN's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest OGN News From Around the Web
Below are the latest news stories about ORGANON & CO that investors may wish to consider to help them evaluate OGN as an investment opportunity.
Organon To Present at the 42nd Annual J.P. Morgan Healthcare ConferenceJERSEY CITY, N.J., December 21, 2023--Organon CEO Kevin Ali and CFO Matthew Walsh to present in a fireside chat at the 42nd Annual J.P. Morgan Healthcare Conference, Tuesday January 9. |
Organon & Lilly Enter Commercialization Agreement in Europe for Two Migraine MedicinesJERSEY CITY, N.J., December 18, 2023--Organon becomes the sole distributor and promoter of Emgality® (galcanezumab) and RAYVOW™ (lasmiditan) in Europe |
Organon To Present at the Piper Sandler 35th Annual Healthcare ConferenceJERSEY CITY, N.J., November 21, 2023--Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29, 2023 at 11:00 a.m. EST. |
Samsung Bioepis & Organon Announce FDA Acceptance of Supplemental Biologics License Application (sBLA) for Interchangeability Designation for HADLIMA™ (adalimumab-bwwd), a Biosimilar to Humira®sBLA based on Phase 4 study which assessed pharmacokinetic similarity between two treatment groups: multi-switching group alternating between Humira and high-concentration HADLIMA vs. Humira-continued groupFiling acceptance reinforces Samsung Bioepis and Organon’s commitment to provide better access to biologic medicines for patients in the United States INCHEON, South Korea and JERSEY CITY, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. and Organon & Co. (NYSE: OGN) today ann |
Organon Reports Results for the Third Quarter Ended September 30, 2023JERSEY CITY, N.J., November 02, 2023--Organon Reports Results for the Third Quarter Ended September 30, 2023 |
Organon and Sempre Health Announce Collaboration on New Service to Help Eligible Patients Save Money and Stay on Their Medication as PrescribedJERSEY CITY, N.J. & SAN FRANCISCO, November 01, 2023--Organon and Sempre Health launch partnership to motivate patients to refill prescriptions on time and improve adherence via supportive pricing program |
Organon Canada Announces Availability of a High-Concentration, Citrate-Free Formulation of HADLIMA®, a Biosimilar to HUMIRA*Organon Canada, a subsidiary of Organon (NYSE: OGN), a global healthcare company with a focus on women's health, today announced the availability of HADLIMA® (adalimumab), a biosimilar for Humira* (adalimumab), in a high-concentration, citrate free (40 mg/0.4 mL) version. The launch of the new higher concentration formulation (40 mg/0.4 mL) (compared to HADLIMA® 40 mg/0.8 mL) offers physicians and patients with more options for the treatment of rheumatoid arthritis (RA), polyarticular juvenile i |
Organon To Report Third Quarter Results and Host Conference Call on November 2, 2023JERSEY CITY, N.J., October 19, 2023--Organon will release third quarter 2023 financial results on November 2, 2023, prior to the webcast and conference call scheduled for 8:30 a.m. EST. |
Lululemon Athletica & Hubbell Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the opening of trading on Wednesday, October 18: |
Goldman Sachs Says These 2 Stocks Could Double Your Money — Here’s Why They Could JumpIn the ever-evolving world of stocks, the year has seen its share of ups and downs. Currently, the stock market grapples with the headwinds of rising interest rates and the resulting surge in bond yields. At the same time, there is reason for optimism. Based on historical patterns, Q4 is typically the year’s strongest for US stocks, and investment bank Goldman Sachs is sticking resolutely with its earlier year-end price target of 4,500 on the S&P 500. “Our baseline view remains that the index wi |